Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03738826 · ClinicalTrials.gov registry record · NA

Reducing Disparities in Medication Adherence in SLE

A NA study of Systemic Lupus Erythematosus, sponsored by Duke University.

Completed
Registry status
NA
Development phase
135
Enrollment target
1
Study location

NCT03738826 is a NA study of Systemic Lupus Erythematosus that has completed, run by Duke University. The registered enrollment target is 135 participants, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03738826, a NA study of Systemic Lupus Erythematosus, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
135 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus

Interventions

  • BEHAVIORAL Behavioral Intervention

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2019-10-02
Est. Completion 2020-06-07
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT03738826

The ClinicalTrials.gov registry entry for NCT03738826 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (64% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Intervention is the first listed.

NCT03738826 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03738826 about?

NCT03738826 is a clinical study titled "Reducing Disparities in Medication Adherence in SLE". This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus

What is the current status of trial NCT03738826?

This trial is currently completed. It is a NA study. The enrollment target is 135 participants. The study started on 2019-10-02. Estimated completion is 2020-06-07.

What conditions does trial NCT03738826 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT03738826?

The interventions under investigation include: Behavioral Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT03738826?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03738826 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.